Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
Flagstar Financial (FLG – Research Report), the Financial sector company, was revisited by a Wall Street analyst yesterday. Analyst Ebrahim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback